About: Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C
Creator	Kumar, Arun Grubor-Bauk, Branka Torresi, Joseph Gowans, Eric Masavuli, Makutiro Mclean, Gary Wijesundara, Danushka
Source	PMC
abstract	Hepatitis C Virus (HCV) infects 2% of the world’s population and is the leading cause of liver disease and liver transplantation. It poses a serious and growing worldwide public health problem that will only be partially addressed with the introduction of new antiviral therapies. However, these treatments will not prevent re-infection particularly in high risk populations. The introduction of a HCV vaccine has been predicted, using simulation models in a high risk population, to have a significant effect on reducing the incidence of HCV. A vaccine with 50 to 80% efficacy targeted to high-risk intravenous drug users could dramatically reduce HCV incidence in this population. Virus like particles (VLPs) are composed of viral structural proteins which self-assemble into non-infectious particles that lack genetic material and resemble native viruses. Thus, VLPs represent a safe and highly immunogenic vaccine delivery platform able to induce potent adaptive immune responses. Currently, many VLP-based vaccines have entered clinical trials, while licensed VLP vaccines for hepatitis B virus (HBV) and human papilloma virus (HPV) have been in use for many years. The HCV core, E1 and E2 proteins can self-assemble into immunogenic VLPs while inclusion of HCV antigens into heterogenous (chimeric) VLPs is also a promising approach. These VLPs are produced using different expression systems such as bacterial, yeast, mammalian, plant, or insect cells. Here, this paper will review HCV VLP-based vaccines and their immunogenicity in animal models as well as the different expression systems used in their production.
has issue date	2017-12-05(xsd:dateTime)
bibo:doi	10.3389/fmicb.2017.02413
bibo:pmid	29259601
has license	cc-by
sha1sum (hex)	e2fbe8d2a00bf0e7041a1b7c9e08c80ef87cb5cb
schema:url	https://doi.org/10.3389/fmicb.2017.02413
resource representing a document's title	Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C
has PubMed Central identifier	PMC5723323
has PubMed identifier	29259601
schema:publication	Front Microbiol
resource representing a document's body	covid:e2fbe8d2a00bf0e7041a1b7c9e08c80ef87cb5cb#body_text
is schema:about of	named entity 'EFFICACY' named entity 'MAMMALIAN' named entity 'NON-' named entity 'ASSEMBLE' named entity 'TREATMENTS' named entity 'PREVENT' named entity 'CAUSE' named entity 'LIVER TRANSPLANTATION' named entity 'USING' named entity 'LEADING' named entity 'HERE' named entity 'INDUCE' named entity 'CORE' named entity 'PARTICLES' named entity 'USE' named entity 'VLP' named entity 'HIGH RISK POPULATION' named entity 'VIRUSES' named entity 'PRODUCTION' named entity 'CLINICAL TRIALS' named entity 'YEARS' named entity 'IMMUNOGENICITY' named entity 'VLPS' named entity 'INCLUSION' named entity 'CELLS' named entity 'native' named entity 'HCV' named entity 'resemble' named entity 'viruses' named entity 'licensed' covid:arg/e2fbe8d2a00bf0e7041a1b7c9e08c80ef87cb5cb named entity 'PAPER' named entity 'WORLDWIDE' named entity 'VIRUS' named entity 'WORLD' named entity 'DRUG USERS' named entity 'INCIDENCE' named entity '80%' named entity 'HIGH-RISK' named entity 'PROTEINS' named entity 'EXPRESSION' named entity 'HIGHLY' named entity 'PREDICTED' named entity 'ADAPTIVE IMMUNE RESPONSES' named entity 'THERAPIES' named entity 'HCV' named entity 'LACK' named entity 'REPRESENT' named entity 'IMMUNOGENIC' named entity 'GENETIC MATERIAL' named entity 'HAVE' named entity 'APPROACH' named entity 'LICENSED' named entity 'LIKE' named entity 'INTRODUCTION' named entity 'BASED' named entity 'INTRAVENOUS DRUG' named entity 'REDUCING' named entity 'NATIVE' named entity 'DIFFERENT' named entity 'INFECTIOUS' named entity 'HETEROGENOUS' named entity 'VIRUS-LIKE PARTICLES' named entity 'PRECLINICAL' named entity 'PRODUCTION' named entity 'VACCINE' named entity 'HEPATITIS C' named entity 'COMPOSED OF' named entity 'VACCINES' named entity 'ANTIGENS' named entity 'USED' named entity 'THESE' named entity 'SIMULATION MODELS' named entity 'BACTERIAL' named entity 'ENTERED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software